Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.
APA
Yu J, Liang H, et al. (2026). Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.. Journal of translational medicine. https://doi.org/10.1186/s12967-026-08105-1
MLA
Yu J, et al.. "Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.." Journal of translational medicine, 2026.
PMID
42001081
같은 제1저자의 인용 많은 논문 (5)
- The highest region of muscle spindle abundance should be the optimal target of botulinum toxin A injection to block muscle spasms in rats.
- Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation.
- KDM5D epigenetically represses FERD3L to inhibit tumor growth in male colorectal cancer.
- Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses.
- Enhancing Risk Stratification in Equivocal Prostate Magnetic Resonance Imaging Lesions: Clinical Utility of Prostate Health Index and Prostate Health Index Density in Prostate Imaging-Reporting and Data System 3.